Byterna | 元码智药

Science & Platform

Circular mRNA and targeted delivery system
for next generation immunotherapies

Circular mRNA (cmRNA) is a class of highly-stable mRNA molecules without free ends. Engineered cmRNA achieves potent and long-lasting protein translation, together with targeted in vivo delivery system, we are transforming the way of CAR-based cell therapies for cancers and autoimmune diseases.

Learn more
The 2023 Nobel Prize in Medicine or Physiology was awarded to Professors Katalin Kariko and Drew Weissman in recognition of their significant breakthroughs in the underlying scientific principles of mRNA therapy. Innovative therapies based on mRNA technology will bring new solutions to a large number of unmet clinical needs. Since 2020, mRNA therapy has experienced rapid development as a new type of biotechnology drug.
Learn more

About

Byterna therapeutics Ltd. (byterna, 元码智药) was co-founded by a diverse team including top talents from drug R&D industry, AI research and bussniess backgrounds. Byterna has invented an array of cutting-edged biotechnologies spanning from scarless RNA circularization, cmRNA chemical modification, AI design, targeted delivery system, etc., aiming to developing safer and accessible cell and gene therapies for global patients.

Learn more